Gabriel Núñez Selected Research

NLR Proteins

1/2017	Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner.
3/2015	A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
6/2014	Infection mobilizes hematopoietic stem cells through cooperative NOD-like receptor and Toll-like receptor signaling.
5/2013	The protein kinase PKR is critical for LPS-induced iNOS production but dispensable for inflammasome activation in macrophages.
12/2008	The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis.
1/2008	A role for Nod-like receptors in autophagy induced by Shigella infection.
1/2008	Intracellular NOD-like receptors in innate immunity, infection and disease.
6/2007	The Nod-like receptor family member Naip5/Birc1e restricts Legionella pneumophila growth independently of caspase-1 activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gabriel Núñez Research Topics

Disease

34	Infections 10/2022 - 11/2006
27	Inflammation (Inflammations) 01/2022 - 02/2003
6	Neoplasms (Cancer) 10/2021 - 12/2011
5	Colitis 10/2022 - 12/2013
5	Cryopyrin-Associated Periodic Syndromes 11/2020 - 03/2003
5	Bacterial Infections (Bacterial Infection) 02/2017 - 06/2007
5	Salmonella Infections (Salmonellosis) 03/2016 - 06/2006
4	Sepsis (Septicemia) 02/2017 - 09/2011
4	Virus Diseases (Viral Diseases) 04/2015 - 12/2006
3	Dysbiosis 10/2020 - 01/2014
3	Skin Diseases (Skin Disease) 01/2018 - 07/2012
3	Macular Degeneration (Age-Related Maculopathy) 06/2015 - 05/2012
3	Melanoma (Melanoma, Malignant) 10/2014 - 05/2013
3	Crohn Disease (Crohn's Disease) 10/2014 - 09/2011
3	Necrosis 10/2014 - 03/2006
3	Carcinogenesis 12/2013 - 12/2008
3	Familial Mediterranean Fever (Periodic Disease) 05/2011 - 03/2003
2	Type 2 Diabetes Mellitus (MODY) 11/2020 - 03/2015
2	Atherosclerosis 11/2020 - 03/2015
2	Alzheimer Disease (Alzheimer's Disease) 11/2020 - 03/2015
2	Periodontitis 01/2016 - 05/2013
2	Pneumonia (Pneumonitis) 01/2016 - 06/2007
2	Shock 11/2015 - 12/2014
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2014 - 12/2011
2	Wounds and Injuries (Trauma) 06/2013 - 09/2011
2	Pseudomembranous Enterocolitis (Pseudomembranous Colitis) 09/2012 - 04/2011
1	IgG Deficiency 10/2022
1	Candidiasis (Moniliasis) 01/2022
1	Communicable Diseases (Infectious Diseases) 01/2022
1	Listeriosis (Listeria Infection) 01/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2022
1	Malaria 12/2021
1	Coinfection 12/2021
1	Glioma (Gliomas) 10/2021
1	Respiratory Syncytial Virus Infections 01/2021
1	Body Remains 02/2017
1	Granuloma 01/2017
1	Fever (Fevers) 02/2016

Drug/Important Bio-Agent (IBA)

28	InflammasomesIBA 01/2022 - 12/2006
14	CytokinesIBA 01/2021 - 12/2008
13	Proteins (Proteins, Gene)FDA Link 01/2017 - 02/2003
8	NLR ProteinsIBA 01/2017 - 06/2007
8	NucleotidesIBA 01/2017 - 06/2006
6	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 10/2008
6	LipopolysaccharidesIBA 10/2020 - 06/2006
6	NF-kappa B (NF-kB)IBA 05/2010 - 03/2003
5	Interleukin-18 (Interleukin 18)IBA 11/2018 - 12/2006
5	Adenosine Triphosphate (ATP)IBA 10/2014 - 06/2007
4	Immunoglobulin G (IgG)IBA 10/2022 - 05/2015
4	Dextran SulfateIBA 10/2022 - 06/2011
4	IronIBA 01/2022 - 06/2015
4	InterleukinsIBA 11/2020 - 12/2006
4	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 04/2015 - 03/2010
4	Interleukin-6 (Interleukin 6)IBA 10/2014 - 03/2006
4	FlagellinIBA 06/2013 - 11/2006
3	Interleukin-17 (Interleukin 17)IBA 01/2022 - 11/2017
3	Virulence Factors (Pathogenicity Factors)IBA 01/2018 - 11/2009
3	Interleukin-22 (IL-22)IBA 02/2017 - 10/2014
3	Interleukin-10 (Interleukin 10)IBA 12/2014 - 01/2012
3	Poly I-CIBA 10/2014 - 12/2006
3	Pattern Recognition ReceptorsIBA 10/2014 - 06/2006
3	ChemokinesIBA 10/2014 - 02/2009
3	Toll-Like Receptors (Toll-Like Receptor)IBA 06/2014 - 09/2008
3	PyrinIBA 05/2011 - 03/2003
2	AntigensIBA 10/2022 - 11/2013
2	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 01/2021 - 03/2015
2	Particulate MatterIBA 10/2014 - 07/2009
2	Leucine (L-Leucine)FDA Link 02/2014 - 05/2009
2	Peptidoglycan (Murein)IBA 05/2013 - 02/2009
2	Double-Stranded RNA (RNA, Double Stranded)IBA 05/2013 - 12/2006
2	CaspasesIBA 07/2009 - 12/2006
2	Interleukin-1beta (Interleukin 1 beta)IBA 01/2009 - 12/2008
2	Mitogen-Activated Protein KinasesIBA 06/2006 - 03/2006
1	OMPA outer membrane proteinsIBA 10/2022
1	Chelating AgentsIBA 01/2022
1	Listeria monocytogenes hlyA protein (listeriolysin O)IBA 01/2022
1	bis(3',5')-cyclic diguanylic acidIBA 01/2022
1	Amino Acids FDA Link 01/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2021
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2021
1	DNA (Deoxyribonucleic Acid)IBA 10/2021
1	Histone DemethylasesIBA 10/2021
1	alpha-hydroxyglutarateIBA 10/2021
1	Antimicrobial PeptidesIBA 01/2021
1	Tamoxifen FDA LinkGeneric 01/2021
1	Complement C3 (C3 Complement)IBA 10/2020
1	lipoteichoic acidIBA 11/2018
1	solonamide BIBA 01/2018
1	staphylococcal delta toxinIBA 11/2017
1	AlarminsIBA 11/2017
1	Peptides (Polypeptides)IBA 11/2017
1	HemopexinIBA 02/2017
1	Heme (Haem)IBA 02/2017
1	Dietary Fiber FDA Link 11/2016
1	Bacterial AntigensIBA 03/2016
1	Filaggrin ProteinsIBA 02/2016

Therapy/Procedure

2	Immunotherapy 10/2021 - 01/2021
2	Therapeutics 01/2018 - 01/2017
2	Ligation 01/2016 - 12/2014